| Viral contamination in biologic manufacture and implications for emerging therapies PW Barone, ME Wiebe, JC Leung, ITM Hussein, FJ Keumurian, ... Nature biotechnology 38 (5), 563-572, 2020 | 182 | 2020 |
| SARS-CoV-2 Omicron BA. 5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern A Aggarwal, A Akerman, V Milogiannakis, MR Silva, G Walker, AO Stella, ... EBioMedicine 84, 2022 | 94 | 2022 |
| SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern A Aggarwal, AO Stella, G Walker, A Akerman, V Milogiannakis, F Brilot, ... medrxiv, 2021.12. 14.21267772, 2021 | 64 | 2021 |
| Effective inactivation of a wide range of viruses by pasteurization A Gröner, C Broumis, R Fang, T Nowak, B Popp, W Schäfer, NJ Roth Transfusion 58 (1), 41-51, 2018 | 51 | 2018 |
| Rapid SARS-CoV-2 inactivation by commonly available chemicals on inanimate surfaces M Gerlach, S Wolff, S Ludwig, W Schäfer, B Keiner, NJ Roth, E Widmer The Journal of hospital infection 106 (3), 633, 2020 | 48 | 2020 |
| Low hepatitis E virus RNA prevalence in a large‐scale survey of United States source plasma donors NJ Roth, W Schäfer, R Alexander, K Elliott, W Elliott‐Browne, J Knowles, ... Transfusion 57 (12), 2958-2964, 2017 | 46 | 2017 |
| IgG3 and IgM identified as key to SARS-CoV-2 neutralization in convalescent plasma pools C Kober, S Manni, S Wolff, T Barnes, S Mukherjee, T Vogel, L Hoenig, ... PLoS One 17 (1), e0262162, 2022 | 43 | 2022 |
| Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia A Aggarwal, AO Stella, G Walker, A Akerman, C Esneau, V Milogiannakis, ... Nature Microbiology 7 (6), 896-908, 2022 | 41 | 2022 |
| The β-galactosidase (Escherichia coli) reaction is partly facilitated by interactions of His-540 with the C6 hydroxyl of galactose NJ Roth, RE Huber Journal of Biological Chemistry 271 (24), 14296-14301, 1996 | 41 | 1996 |
| Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light. E Ben-Hur, WS Chan, Z Yim, MM Zuk, V Dayal, N Roth, E Heldman, ... Developments in biologicals 102, 149-155, 2000 | 40 | 2000 |
| Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers NJ Roth, HO Dichtelmüller, F Fabbrizzi, E Flechsig, A Gröner, ... Transfusion 60 (11), 2661-2674, 2020 | 39 | 2020 |
| Robustness of nanofiltration for increasing the viral safety margin of biological products S Caballero, JM Diez, FJ Belda, M Otegui, S Herring, NJ Roth, D Lee, ... Biologicals 42 (2), 79-85, 2014 | 38 | 2014 |
| Studies of Glu-416 Variants of β-Galactosidase (E. coli) Show that the Active Site Mg2+ is Not Important for Structure and Indicate that the Main Role of Mg2+ is to … S Lo, ML Dugdale, N Jeerh, T Ku, NJ Roth, RE Huber The protein journal 29, 26-31, 2010 | 36 | 2010 |
| His-357 of β-Galactosidase (Escherichia coli) Interacts with the C3 Hydroxyl in the Transition State and Helps To Mediate Catalysis NJ Roth, B Rob, RE Huber Biochemistry 37 (28), 10099-10107, 1998 | 34 | 1998 |
| Emergence and antibody evasion of BQ, BA. 2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level A Akerman, V Milogiannakis, T Jean, C Esneau, MR Silva, T Ison, ... EBioMedicine 90, 2023 | 33 | 2023 |
| His-391 of β-galactosidase (Escherichia coli) promotes catalyes by strong interactions with the transition state RE Huber, IY Hlede, NJ Roth, KC McKenzie, KK Ghumman Biochemistry and Cell Biology 79 (2), 183-193, 2001 | 33 | 2001 |
| Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies K Cai, A Gröner, HO Dichtelmüller, F Fabbrizzi, E Flechsig, R Gajardo, ... Transfusion 53 (9), 1894-1905, 2013 | 32 | 2013 |
| Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics … HO Dichtelmüller, L Biesert, F Fabbrizzi, A Falbo, E Flechsig, A Gröner, ... Transfusion 51 (7), 1412-1430, 2011 | 27 | 2011 |
| Mechanistic insights into flow-dependent virus retention in different nanofilter membranes R Leisi, E Widmer, B Gooch, NJ Roth, C Ros Journal of Membrane Science 636, 119548, 2021 | 25 | 2021 |
| Estimating viral titres in solutions with low viral loads C Brownie, J Statt, P Bauman, G Buczynski, K Skjolaas, D Lee, J Hotta, ... Biologicals 39 (4), 224-230, 2011 | 24 | 2011 |
